Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

Study: Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data. Image Credit: memorisz / Shutterstock A team of researchers at the University of Bern ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...